Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...

Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled ...

Credence Research Inc. has released a new study on the Blood Glucose Monitoring Devices Market. According the report the ...

Instead of making life easier for medical device companies, the FDA’s new wearables guidance makes the market more complex.

Fortem Technologies, the global leader in airspace security and counter-drone solutions, today announced it has completed what it believes is the first autonomous 5-vs-5 drone intercept with safe ...

Shore Group, a traditional outsource staffing provider since 2006, today announced it has completed a three-year transformation into an AI-enabled operations company and launched Shore Digital ...

This article discusses the best growth stocks to buy right now.

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

Jacob Steven Leach, DexCom, Inc.'s President and CEO who will summarize our recent highlights and ongoing strategic initiatives. Please note that there are also slides available related to our fourth ...

As patients and employers look for alternatives to pricey GLP-1 drugs, Silicon Valley startup Twin Health is using AI and wearable sensors to help people make healthier choices. Rodney Buckley has ...

DexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the approval of the company’s upcoming 15-day G7 continuous glucose monitor (CGM).